Engineered riboflavin–cerium oxide nanoparticles for enhanced phototoxicity toward triple-negative breast cancer cells
1
Issued Date
2025-01-01
Resource Type
eISSN
25160230
Scopus ID
2-s2.0-105018770154
Journal Title
Nanoscale Advances
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nanoscale Advances (2025)
Suggested Citation
Wongpan A., Nuchpun S., Tana-Atsawapon N., Luksirikul P., Suriyarak S., Artsanthia J., Katewongsa K.P. Engineered riboflavin–cerium oxide nanoparticles for enhanced phototoxicity toward triple-negative breast cancer cells. Nanoscale Advances (2025). doi:10.1039/d5na00555h Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112701
Title
Engineered riboflavin–cerium oxide nanoparticles for enhanced phototoxicity toward triple-negative breast cancer cells
Corresponding Author(s)
Other Contributor(s)
Abstract
Cerium oxide nanoparticles (CeO<inf>2</inf> NPs) are redox-active nanomaterials with promising applications in biomedical engineering. In this study, CeO<inf>2</inf> NPs are functionalized with riboflavin to enhance cellular uptake and introduce photoresponsive properties. In vitro studies demonstrate that the resulting riboflavin-modified CeO<inf>2</inf> (Rf–CeO<inf>2</inf>) NPs exhibit low toxicity under dark conditions but exert significantly enhanced cytotoxicity against triple-negative breast cancer (TNBC) MDA-MB-231 cells upon ultraviolet (UV) irradiation. This light-triggered cytotoxic effect is attributed to the photoactive nature of riboflavin, which alters reactive oxygen species (ROS) generation upon UV exposure. Our findings highlight the potential of Rf–CeO<inf>2</inf> NPs as a selectively light-activated nanoplatform for targeted cancer therapy that integrates redox functionality and photoactivity into a single engineered nanomaterial, particularly for TNBC and other aggressive cancer subtypes.